Flavivirus inhibitors

A compound of general formula (I):

• wherein:
• m and n are each independently selected from 0, 1 and 2;
• R1a and R1b are independently selected from H and C1-6alkyl optionally substituted with one or more substituents selected from:
• hydroxy, OC1-3alkyl, halogen, NH2, NHCOC1-6alkyl, NHCOOC1-6alkyl, NHC(═O)NHC1-6alkyl, NHSO2C1-6alkyl, NHC1-3alkyl, N(C1-3alkyl)2, or a cyclic amine selected from aziridine, azetidine, pyrrolidine, pyperidine, morpholine, piperazine, N-methylpyperazine;
• or R1a and R1b are linked together to form a C3-6-cycloalkyl ring or a C4-6-heterocycloalkyl ring;
• or R1a is linked to R3 to form a partially unsaturated aromatic or heteroaromatic bicycle;
• or R1b doesn't exist and C—R1a is C═CH2;
• R2a and R2b are independently selected from H and C1-6alkyl optionally substituted with one or more substituents selected from:
• hydroxy, OC1-3alkyl, halogen, NH2, NHCOC1-6alkyl, NHCOOC1-6alkyl, NHC1-3alkyl, N(C1-3alkyl)2, or a cyclic amine selected from aziridine, azetidine, pyrrolidine, pyperidine, morpholine, piperazine, N-methylpyperazine;
• or R2a and R2b are linked together to form a C3-6-cycloalkyl ring or a C4-6-heterocycloalkyl ring;
• or any two of R1a and R2a or of R1b and R2b are linked together to form a C3-6cycloalkyl or a C3-6 heterocycloalkyl;
• R3 is heterocycloalkyl, aromatic or heteroaromatic ring, each of said heterocycloalkyl, aromatic or heteroaromatic ring being optionally substituted with one or more substituents independently selected from halogen, hydroxy, NH2, NHCOC1-6alkyl, NHCOOC1-6alkyl, NHC(═O)NHC1-6alkyl, NHSO2C1-6alkyl, NHC1-3alkyl, N(C1-3alkyl)2, C1-6alkyl, haloC1-6alkyl, C1-6alkoxy, cyano, B(OH)2, aryl, heteroaryl wherein said aryl or heteroaryl ring are optionally substituted with one or more substituents each independently selected from halogen, hydroxy, cyano, NH2, NHCOC1-6alkyl, NHCOOC1-6alkyl, NHC1-3alkyl, N(C1-3alkyl)2, C3-6cycloalkyl, aziridine, azetidine, pyrrolidine, pyperidine, morpholine, piperazine, N-methylpyperazine, C1-6alkyl, C1-6alkoxy, wherein said C1-6 alkyl, C1-6alkoxy are optionally substituted with one or more halogen, hydroxy, NH2, NHCOCH3, NHCOOC1-6alkyl, NHC1-3alkyl, N(C1-3alkyl)2, aziridine, azetidine, pyrrolidine, pyperidine, morpholine, piperazine and N-methylpyperazine;
• R4 is a ring of formula (II):
• wherein
• R6 is CF3, F, Cl, CN or C1-3alkyl, cyclopropyl, CHF2;
• X is CR7 or N;
• R7 is at each occurrence independently selected from H, halogen, C1-6alkyl, C1-6alkoxy, haloC1-6alkyl, hydroxy;
• or R4 is 4-trifluoromethylphenyl, thiophene, thiazole, imidazole, pyrazole, oxazole, oxadiazole, naphthalene, quinoline, isoquinoline, quinazoline or napthyridine, wherein each of said ring is optionally substituted with one or more substituents selected from halogen, C1-6alkyl, hydroxy, haloC1-6alkyl, C1-6alkoxy, NH2, NHC(O)C1-6alkyl, CN;
• or R4 is phenyl and R3 is a phenyl ring substituted with an heteroaromatic ring optionally substituted with one or more substituents selected from halogen, C1-6alkyl, C1-6alkoxy;
• R5 is H, C1-6alkyl, C1-6haloalkyl or halogen;
• or a pharmaceutically acceptable salt, tautomer, solvate, or stereoisomer thereof, provided that compounds indicated below are not included: